GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Fluticasone propionate/Salmeterol
Drug: Umeclidinium bromide/Vilanterol
Drug: Placebo ACCUHALER/DISKUS
Drug: Placebo NDPI

First Posted Date: 2013-04-02

Last Posted Date: 2017-09-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 717

Registration Number: NCT01822899

Locations: 🇪🇸
GSK Investigational Site, Valladolid, Spain

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

Phase 1

Terminated

Conditions: Infections, Bacterial

Interventions: Drug: GSK1322322 Initial fit for purpose tablets
Drug: GSK1322322 for injection
Drug: Placebo tablets
Drug: GSK1322322 over granulated tablets
Drug: Placebo injection
Drug: GSK1322322 intended commercial tablets
Drug: 13C-GSK1322322 stable isotope powder

First Posted Date: 2013-03-26

Last Posted Date: 2019-01-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT01818011

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers

Phase 1

Completed

Conditions: Respiratory Disorders

Interventions: Drug: Single IV dose of GSK2862277
Drug: Matching placebo single dose IH
Drug: Repeat IV dose of GSK2862277
Drug: Matching placebo repeat dose IV infusion
Drug: Matching placebo single dose IV infusion
Drug: Single IH dose of GSK2862277
Drug: Repeat IH dose selected of GSK2862277 from Part 2
Drug: Matching placebo repeat dose IH

First Posted Date: 2013-03-26

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 54

Registration Number: NCT01818024

Locations: 🇬🇧
GSK Investigational Site, Harrow, Middlesex, United Kingdom

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Umeclidinium/vilanterol
Drug: Fluticasone propionate/salmeterol
Drug: Placebo

First Posted Date: 2013-03-25

Last Posted Date: 2017-11-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 707

Registration Number: NCT01817764

Locations: 🇺🇦
GSK Investigational Site, Yalta, Ukraine

An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II Diabetes

Phase 4

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Metformin Small Pack
Drug: Metformin Large Pack

First Posted Date: 2013-03-25

Last Posted Date: 2017-01-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 31

Registration Number: NCT01817777

Locations: 🇦🇷
GSK Investigational Site, Tucumán, Argentina

Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

Phase 3

Completed

Conditions: Allergic Rhinitis
Seasonal Allergic Rhinitis

Interventions: Drug: Placebo
Drug: Fluticasone propionate

First Posted Date: 2013-03-25

Last Posted Date: 2014-04-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 626

Registration Number: NCT01817790

Locations: 🇺🇸
PPD Corporate Headquarters, Wilmington, North Carolina, United States

Retapamulin Microdialysis Feasibility Study

Phase 1

Completed

Conditions: Skin Infections, Bacterial

Interventions: Drug: Retapamulin Microdialysis

First Posted Date: 2013-03-18

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 3

Registration Number: NCT01812382

Locations: 🇺🇸
GSK Investigational Site, Gainesville, Florida, United States

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukaemia, Lymphoblastic

Interventions: Drug: chlorambucil, tablets

First Posted Date: 2013-03-11

Last Posted Date: 2015-06-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 5

Registration Number: NCT01808326

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Proof of Concept (POC) in Patients With Ischaemic Stroke

Phase 2

Terminated

Conditions: Cerebrovascular Accident

Interventions: Drug: Placebo
Drug: GSK249320 100/mg

First Posted Date: 2013-03-11

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 134

Registration Number: NCT01808261

Locations: 🇬🇧
GSK Investigational Site, Torquay, United Kingdom

A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Phase 1

Terminated

Conditions: Multiple Sclerosis, Relapsing-Remitting

First Posted Date: 2013-03-11

Last Posted Date: 2017-06-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT01808482

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy